Data from EMC - Curated by Toby Galbraith - Last updated 13 September 2017

Licensing authority

EMA (European Medicines Agency)

Indication(s)

Zydelig is indicated in combination with an anti-CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL):
- who have received at least one prior therapy, or
- as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.

Zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

Visit Chronic Lymphocytic Leukaemia (CLL)

IL-17A in Psoriasis

Experts discuss new targeted therapies for psoriasis at the European Association of Dermatology and Venereology (EADV) Congress.

Visit IL-17A in Psoriasis

Related Content

More information

Category Value
Agency product number EMEA/H/C/003843
Orphan designation No
Date First Approved 18-09-2014
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Gilead Sciences International Ltd
Warnings This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions